Группа авторов

Transition of Care


Скачать книгу

were lost to follow-up. Introduction of a young person clinic increased the numbers of patients being transferred to specialist adult services but failed to improve engagement [22]. Although there is emerging evidence about how to organize transition, there is a need to identify which patients are at risk of drifting away from endocrine care and to evaluate the impact of a successful transition [22]. A recent study in the UK estimated the numbers of patients with CAH attending specialist adult services between 2 and 5%. Inadequate transition to adult services was emphasized as a potential explanation [15].

      Management of Transition in Patients with Nonclassic CAH

      A subset of patients with nonclassic CAH is diagnosed during childhood with early onset and rapid progression of pubarche or bone age, or in adolescent women with hirsutism. These children are often treated with hydrocortisone to suppress adrenal hormones and prevent rapid advancement of bone age that could adversely affect adult final height. However, lifetime GC therapy is not warranted in these patients. Endocrine Society guidelines stated that treated patients with nonclassic CAH be given the option of discontinuing therapy when symptoms resolve, and that adult men do not require daily GC treatment [58]. Adult males with nonclassic CAH do not require endocrine care, but as evidence-based longitudinal outcome data from a large cohort of patients are not available, some teams considered an endocrine assessment every 5 years [25].

Knowledge goals for patients with CAH in transition –Understand that CAH is a lifelong disease that is genetically inherited –Understand the medication regimen, be able to self-manage stress doses of glucocorticoid during illness, including self-administration of parenteral hydrocortisone –Knowledge of surgical history and physical implications for women –Knowledge of infertility risks but also that fertility and satisfying sexual experiences can be achieved
Monitoring of the efficacy of glucocorticoid replacement therapy –Early-morning serum concentrations of 17-OHP, Δ4-androstenedione, total testosterone, SHBG approximately every 6 –12 months –Diurnal 17-OHP curve with dried blood spots if available
Monit oring of the efficacy of mineralocorticoid replacement –Blood pressure –Plasma electrolytes –Early-morning plasma renin activity concentration
Periodic measurements and/or monitoring of the following –Weight –Lipid profile –Blood pressure –Glycemia –Bone mineral density
Assessment of male gonadic function and fertility –Testicular adrenal rest by ultrasonography –Sperm analysis –Fertility preservation –Hormonal measurements: total testosterone, LH, FSH
Assessment of female gonadic function and fertility –Gynecological care –Clinical and biological hyperandrogenism, menstrual cycle –Sexuality –Hormonal measurements: progesterone, estradiol, FSH
Genetic counseling
Psychological support
CAH, congenital adrenal hyperplasia; 17-OHP, 17-hydroxyprogesterone; SHBG, sexual hormonebinding globulin; LH, luteinizing hormone; FSH, follicle-stimulating hormone.

      Conclusions

      Patients with CAH must experience a transition from pediatric to adult care, because it is a chronic disease with the need of a specific treatment and the risk of various long-term complications. Transition of adolescents to adult care involves changes in treatment goals. Careful monitoring, extensive education, and long-term follow-up should be required